Soligenix Inc. (NASDAQ: SNGX), a clinical-stage biotechnology company focused on rare diseases and public health solutions, has rejuvenated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (CTCL), placing fresh expertise and leadership at the center of its HyBryte(TM) development program. This strategic move signals the company's deepening commitment to advancing its pipeline agents in CTCL and aligning clinical strategy with evolving standards of care.
Soligenix revealed updates to its U.S. Medical Advisory Board for CTCL designed to support the clinical advancement of HyBryte (synthetic hypericin) and related therapies. Specifically, the updates include the addition of new members and the retirement of prior advisors. The company noted that the updated board will provide critical insight as Soligenix navigates the complexities of CTCL and the evolving therapeutic landscape.
The decision to refresh the advisory team reflects recognition that commercialization preparation in the CTCL space, evolving regulatory expectations, and the need for robust trial designs demand expert insight. HyBryte, a topical therapy, is being investigated for the treatment of early-stage CTCL, a rare form of non-Hodgkin lymphoma that primarily affects the skin. The company aims to leverage the new board's expertise to optimize clinical trial protocols and prepare for potential regulatory submissions.
For more details on the advisory board updates, readers can refer to the full announcement at https://ibn.fm/ueKOC. Additionally, ongoing updates about Soligenix are available in the company's newsroom at https://IBN.fm/SNGX.
The CTCL treatment landscape has seen limited innovation, with existing therapies often associated with significant side effects or limited efficacy. HyBryte, which utilizes synthetic hypericin activated by visible light, offers a novel photodynamic therapy approach that may provide a favorable safety profile. The advisory board's guidance will be crucial in differentiating HyBryte from current standards of care and addressing unmet medical needs.
Soligenix's move comes amid a broader effort to strengthen its rare disease portfolio. The company also has programs in other areas, including radiation countermeasures and vaccines, but CTCL remains a key focus. By aligning with top clinicians and researchers, Soligenix aims to accelerate the path to market for HyBryte and potentially offer patients a new treatment option.
